New Thalassemia Cases Drop from 725 in 2021 to 458 in 2025
Maharashtra has witnessed a significant decline in the number of new thalassemia cases over the past five years, according to data released by the State Health Department. Health officials have credited the reduction to increased awareness, state-sponsored bone marrow transplant (BMT) programmes, and strengthened screening initiatives aimed at early detection and prevention.
The data shows a consistent downward trend in new thalassemia cases, with 725 cases recorded in 2021, 628 in 2022, 566 in 2023, 552 in 2024, and 458 in 2025.
State Expands Bone Marrow Transplant Programme
Experts believe that Maharashtra’s proactive approach towards bone marrow transplantation, currently considered the only definitive cure for thalassemia, has played a key role in reducing the disease burden.
Speaking on the development, Dr Suhas Mohanlkar, Deputy Director of Hemoglobinopathies in the State Health Services, revealed that the government sponsored bone marrow transplants for 90 children during the last year.
The state has also intensified efforts to identify suitable donors and improve access to life-saving treatment for patients suffering from severe forms of the disease.
Mandatory HPLC Testing for Pregnant Women Under Consideration
In a major preventive initiative, the Maharashtra government recently constituted an 11-member expert committee to formulate a proposal for making High-Performance Liquid Chromatography (HPLC) testing mandatory for all pregnant women.
The HPLC test helps detect thalassemia at an early stage in unborn children, enabling couples to make informed medical decisions. Health authorities believe that widespread prenatal screening could significantly reduce the number of children born with Thalassemia Major, the most severe form of the disorder.
Free Bone Marrow Matching Drives Launched Across Key Cities
To strengthen donor availability and improve transplant success rates, the Health Department has launched free bone marrow cross-matching drives under the “Vision 2025: Thalassemia-Free India Program.”
The initiative is currently being conducted in several cities, including Pune, Chhatrapati Sambhajinagar, and Nanded, with the objective of connecting eligible donors with patients in need of transplants.
Experts Highlight Cost Benefits of Early Detection
Medical experts have emphasized that while bone marrow transplantation offers a permanent cure, the procedure remains financially challenging for many families.
“As of now, a bone marrow transplant remains the only definitive cure for thalassemia, which is a highly expensive procedure. In comparison, testing is remarkably affordable,” said Dr Kannan Subramanian, Senior Hemato-Oncologist at KEM Hospital, Pune.
According to experts, a bone marrow transplant can cost around ₹12 lakh, whereas a simple screening test such as hemoglobin electrophoresis costs approximately ₹1,000. They stress that early diagnosis and preventive screening remain the most cost-effective strategies for reducing the incidence of thalassemia.
Maharashtra’s Multi-Pronged Strategy Showing Results
Health officials believe that the combination of state-funded transplants, free donor matching campaigns, prenatal screening initiatives, and public awareness programmes is yielding positive outcomes. As Maharashtra moves towards its goal of a thalassemia-free future, the state’s model is increasingly being viewed as a potential blueprint for tackling hereditary blood disorders across India.
